Hepatitis B

Metabasis reports $1M milestone payment for remofovir

Published in Hepatitis Weekly, May 10th, 2004

Metabasis Therapeutics, Inc., (Metabasis) announced that Valeant Pharmaceuticals International has agreed to pay a $1 million milestone payment to Metabasis in recognition of a decision to initiate a phase II clinical evaluation of remofovir (formerly known as Hepavir B) in patients with chronic hepatitis B infection.

Valeant licensed remofovir, an orally active prodrug of the proven antiviral agent adefovir, from Metabasis in October 2001 and is primarily responsible for the clinical development of the drug.

The decision to proceed with development was based on results recently obtained from the first clinical evaluation of remofovir in patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry